Identification of cancer genes by mutational profiling of tumor genomes

被引:14
作者
Benvenuti, S [1 ]
Arena, S [1 ]
Bardelli, A [1 ]
机构
[1] Univ Turin, Sch Med, Oncogenom Ctr, Inst Canc Res & Treatment,IRCC, Candiolo, To, Italy
来源
FEBS LETTERS | 2005年 / 579卷 / 08期
关键词
cancer genome; oncogenomics; gene family; tailored therapies; mutational analysis;
D O I
10.1016/j.febslet.2005.02.015
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
It is now widely accepted that cancer is a genetic disease and that alterations in the DNA sequence underlie the development of every neoplasm. The identification of mutated genes that are causally implicated in oncogenesis ('cancer genes') has been a major goal in medical sciences for the last two decades. The availability of the human genome sequence coupled to the introduction of high throughput sequencing technologies has created an unprecedented opportunity in this field. It is now possible to perform mutational studies of entire cancer genomes thus providing a complete description of mutations underlying human oncogenesis. The recent identification of high frequency mutations in the BRAF and PI3K genes suggests that many more cancer genes remain to be discovered. In this review, we consider how the systematic mutational analysis of gene families in individual neoplasms has led to the identification of a number of cancer genes and how this information is influencing the treatment of cancer. (c) 2005 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1884 / 1890
页数:7
相关论文
共 46 条
[1]   Protein tyrosine phosphatases in the human genome [J].
Alonso, A ;
Sasin, J ;
Bottini, N ;
Friedberg, I ;
Friedberg, I ;
Osterman, A ;
Godzik, A ;
Hunter, T ;
Dixon, J ;
Mustelin, T .
CELL, 2004, 117 (06) :699-711
[2]   The PIK3CA gene is mutated with high frequency in human breast cancers [J].
Bachman, KE ;
Argani, P ;
Samuels, Y ;
Silliman, N ;
Ptak, J ;
Szabo, S ;
Konishi, H ;
Karakas, B ;
Blair, BG ;
Lin, C ;
Peters, BA ;
Velculescu, VE ;
Park, BH .
CANCER BIOLOGY & THERAPY, 2004, 3 (08) :772-775
[3]   Mutational analysis of the tyrosine kinome in colorectal cancers [J].
Bardelli, A ;
Parsons, DW ;
Silliman, N ;
Ptak, J ;
Szabo, S ;
Saha, S ;
Markowitz, S ;
Willson, JKV ;
Parmigiani, G ;
Kinzler, KW ;
Vogelstein, B ;
Velculescu, VE .
SCIENCE, 2003, 300 (5621) :949-949
[4]   Mutational analysis of gene families in human cancer [J].
Bardelli, A ;
Velculescu, VE .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2005, 15 (01) :5-12
[5]   Metastasis genes: A progression puzzle [J].
Bernards, R ;
Weinberg, RA .
NATURE, 2002, 418 (6900) :823-823
[6]   Oncogenic kinase signalling [J].
Blume-Jensen, P ;
Hunter, T .
NATURE, 2001, 411 (6835) :355-365
[7]  
DAVIES H, 2002, NATURE
[8]   Imatinib as a paradigm of targeted therapies [J].
Druker, BJ .
ADVANCES IN CANCER RESEARCH, VOL 91, 2004, 91 :1-+
[9]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[10]   Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry [J].
Falini, B ;
Mason, DY .
BLOOD, 2002, 99 (02) :409-426